THE CASE OF PSORIATIC ERYTHRODERMA AND SEVERE COMORBID PSORIATIC ARTHRITIS

Abstract

Early diagnosis of psoriatic arthritis (PsA) is necessary for timely treatment and prevention of the disease progression with destruction of the joints. In most patients, comorbid PsA develops many years after the debut of the skin process. Consequently, the main role in timely diagnosis of PsA is played by a dermatologist, who is able to identify its initial signs and refer the patient to a rheumatologist. Early initiation of systemic therapy with the use of modern biological agents for progressive psoriatic arthritis and severe psoriasis can prevent the development of irreversible disability.

Keywords

psoriasis / psoriatic arthritis / biological therapy

References

[1] Myers W. A., Gottlieb A. B., Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin. Dermatol. 2006; 24(5): 438-47.

[2] Landells I., MacCallum C., Khraishi M. The role of the dermatologist in identification and treatment of the early stages of psoriatic arthritis. Skin Therapy Lett. 2008; 13(4): 4-7.

[3] Gottlieb A., Korman N.J., Gordon K.B., Feldman S.R., Lebwohl M., Koo J.Y., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J. Am. Acad. Dermatol. 2008; 58(5): 851-64.

[4] Lebwohl M. Psoriasis. Lancet. 2003: 361(9364): 1197-204.

[5] Myers W., Opeola M., Gottlieb A.B. Common clinical features and disease mechanisms of psoriasis and psoriatic arthritis. Curr. Rheumatol. Rep. 2004; 6(4): 306-13.

[6] Кочергин Н.Г., Смирнова Л.М., Потекаев Н.Н., Билалова У.В. Псориаз: коморбидности и комедикации. Врач. 2009; (5): 15-20.

[7] Stern R.S. The epidemiology of joint complaints in patients with psoriasis. J. Rheumatol. 1985; 12(2): 315-20.

[8] Бадокин В.В. Современная терапия псориатического артрита. Consilium Medicum. 2005; 7(3): 181-8. http://old.consilium-medicum.com/media/consilium/05_03/181.shtml

[9] Quershi A.A., Husni M.E., Mody E. Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. Semin. Cutan. Med. Surg. 2005; 24(1): 46-51.

[10] Weinstein G.D., Gottlieb A.B., eds. Therapy of Moderate to Severe Psoriasis, New York: Marcel Dekker; 2003.

[11] Castillo V.L., Castillo I.L., Rodriguez P., Ricart J.M. Periodontal disease in patients with chronic plaque psoriasis. 27th EADV Congress, 12-16 Sept. 2018, Paris; 2018. P1834. https://eadvprogram.m-anage.com/ProgramSearch/Abstract?eventname=eadvparis2018&language=en-GB&abstractid=6896.

[12] Ferrandiz C., Pujol R.M., Garcia-Patos V., Bordas X., Smandia J.A. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J. Am. Acad. Dermatol. 2002; 46(6): 867-73.

[13] Henseler T., Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J. Am. Acad. Dermatol. 1985; 13(3): 450-6.

[14] Cohen M.R., Reda D.J., Clegg D.O. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J. Rheumatol. 1999; 26(8): 1752-6.

[15] Gladman D.D., Anhorn K.A., Schachter R.K., Mervart H. HLA antigens in psoriatic arthritis. J. Rheumatol. 1986; 13(3): 586-92.

[16] Williamson L., Dalbeth N., Dockerty J.L. Gee B.C., Weatherall R., Wordsworth B.P. Extended report: nail disease in psoriatic arthritis - clinically important, potentially treatable and often overlooked. Rheumatology (Oxford). 2004; 43(6): 790-4.

[17] Alenius G.M. Psoriatic arthritis - new insights give new options for treatment. Curr. Med. Chem. 2007; 14(3): 359-66.

[18] Yates V.M., Watkinson G., Kelman A. Further evidence for an association between psoriasis, Crohn’s disease and ulcerative colitis. Br. J. Dermatol. 1982; 106(3): 323-30.

[19] Hellgren L. Association between rheumatoid arthritis and psoriasis in total populations. Acta Rheumatol. Scand. 1969; 15(4): 316-26.

[20] Brockbank J., Gladman D. Diagnosis and management of psoriatic arthritis. Drugs. 2002; 62(17): 2447-57.

[21] Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., Mielants H.; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006; 54(8): 2665-73.

[22] Ory P.A., Gladman D.D., Mease P.J. Psoriatic arthritis and imaging. Ann. Rheum. Dis. 2005; 64(Suppl. 2): ii55-7.

[23] Nash P., Clegg D.O. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann. Rheum. Dis. 2005; 64(Suppl. 2): ii74-7.

[24] Black R.L., O’Brien W.M., Vanscott E.J., Auerbach R., Eisen A.Z., Bunim J.J. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA. 1964; 189: 743-7.

[25] Willkens R.F., Williams H.J., Ward J.R., Egger M.J., Reading J.C., Clements P.J., et al. Randomized, double-blind, placebo-controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984; 27(4): 376-81.

[26] Clegg D.O., Reda D.J., Mejias E., Cannon G.W., Weisman M.H., Taylor T., Budiman-Mak E., et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996; 39(12): 2013-20.

[27] Kaltwasser J.P., Nash P., Gladman D., Rosen C.F., Behrens F., Jones P., et al.; Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004; 50(6): 1939-50.

[28] Курдина М.И. Антицитокиновая терапия - новое направление в лечении псориаза. Вестник дерматологии и венерологии. 2005; (1): 3-8.

[29] Чичасова Н.В., Лукина Г.В., Сигидин Я.А., Имаметдинова Г.Р., Насонов Е.Л. Опыт лечения ревматоидного артрита препаратом Ремикейд (инфликсимаб). Русский медицинский журнал. Ревматология. 2005; (24): 1590-4.

[30] Смирнова Л.М., Кочергин Н.Г. Инфликсимаб при псориазе: европейский взгляд. Русский медицинский журнал. Дерматология. 2006; (5): 362-8. https://www.rmj.ru/articles/obshchie-stati/Infliksimab_pri_psoriaze_evropeyskiy_vzglyad/

[31] Sawyer L., Malottki K., Yasmeen M., et al. Interleukin-17 and interleukin-23 targeted treatments for moderate to severe plaque psoriasis: a systemic review and network meta-analysis of PASI response. 27th EADV Congress, 12-16 Sept. 2018, Paris; 2018. P1901. https://eadvprogram.m-anage.com/ProgramSearch/Abstract?eventname=eadvparis2018&language=en-GB&abstractid=7726

[32] Кочергин Н.Г. Псориаз: последние новости. Consilium Medicum. Дерматология. 2007; (2): 14-7.

[33] Soriano E.R., McHugh N.J. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J. Rheumanol. 2006; 33(7): 1422-30.

[34] Antoni C., Krueger G.G., de Vlam K., Birbara C., Beutler A., Guzzo C., Zhou B., et al.; IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. 2005; 64(8): 1150-7.

[35] Mease P.J., Gladman D.D., Ritchlin C.T., Ruderman E.M., Steinfeld S.D., Choy E.H., et al. Sharp JT; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52(10): 3279-89.

[36] Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004; 50(7): 2264-72.

[37] Queiro-Silva R., Torre-Alonso J.C., Tinture-Eguren T., Lopez-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann. Rheum. Dis. 2003; 62(1): 68-70.

RIGHTS & PERMISSIONS

Eco-Vector